Coronary plaque AI tools face the next hurdle: reimbursement

Coronary plaque analysis may be one of the most commercially revealing use cases in medical AI because it sits at the intersection of imaging sophistication and payment friction. Even when software can extract more information from scans, adoption will stall if providers cannot clearly bill for the work or justify the cost.

That makes reimbursement strategy as important as algorithm performance. Healthcare AI vendors often focus on accuracy, but buyers need a complete business case: who pays, which code applies, what documentation is required, and whether the software changes downstream management enough to matter economically.

This is especially relevant in cardiovascular imaging, where enhanced plaque characterization could influence treatment decisions and risk stratification. The clinical value proposition is real, but value must be translated into administrative language before health systems will treat the software as a routine part of care.

The broader lesson is that reimbursement is becoming a filter for which AI products survive. Tools that only demonstrate technical novelty may struggle, while those that can prove both clinical and financial utility will have a better chance of moving from pilot to standard practice.